BOSTON: Neurotrope, Inc (NTRP) has announced the initiation of a phase 2b clinical trial of lead candidate Bryostatin 1 for the treatment of Alzheimer’s disease.
The phase 2b trial is a randomised, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and efficacy of Bryostatin 1 in the treatment of moderately severe to severe Alzheimer’s disease. The study, which plans to enrol 150 patients, is currently recruiting subjects at five trial sites.